TREATMENT OUTCOMES OF KAWASAKI DISEASE IN CHILDREN AT NGHE AN OBSTETRICS AND PEDIATRICS HOSPITAL
##plugins.themes.vojs.article.main##
Abstract
Objective: To assess the outcomes of intravenous immunoglobulin (IVIG) therapy and the evolution of coronary artery lesions (CAL) in children with Kawasaki disease at Nghe An Obstetrics and Pediatrics Hospital (2024–2026).
Methods: A case-series study of 53 children with confirmed Kawasaki disease treated at the hospital from January 2024 to March 2026.
Results: All children received IVIG within the first 10 days of illness, at a mean febrile day of 7.3 ± 0.9, with no adverse effects. The first-dose response rate was 88.7% and 11.3% were IVIG-resistant; all responded to a second dose. IVIG resistance was significantly associated with the incomplete form (66.7% vs 21.3%; p = 0.036) and with more severe coronary artery lesions (moderate dilation 66.7% vs 4.3%; p = 0.001). After infusion, inflammatory markers (white blood cells, neutrophils, ESR, CRP) decreased significantly (p < 0.001). Acute-phase CAL prevalence was 56.6% (mild dilation 45.3%, moderate dilation 11.3%, no giant aneurysm), declining to 11.3% (predominantly mild) at weeks 6–8, with 80.0% (24/30) of initial lesions fully resolved.
Conclusion: Early IVIG within 10 days yielded favorable outcomes; the incomplete form and severe CAL showed a statistically significant association with IVIG resistance, although larger studies are needed to confirm these findings.
##plugins.themes.vojs.article.details##
Keywords
Kawasaki disease, children, IVIG, IVIG resistance, coronary artery
References
2. McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135(17):e927-e999. https://doi.org/10.1161/cir.0000000000000484
3. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the American Heart Association. Circulation 2004;110(17):2747-2771. https://doi.org/10.1161/01.cir.0000145143.19711.78
4. Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis 2018;21(1):64-69. https://doi.org/10.1111/1756-185x.13220
5. Kim BJ, Choi A, Kim HS et al. Changes in the clinical characteristics of Kawasaki disease after coronavirus disease (COVID-19) pandemic: a database analysis. J Korean Med Sci 2022;37(20):e141. https://doi.org/10.3346/jkms.2022.37.e141
6. Yu H, Ni C, Xia Y et al. Characteristics of Kawasaki disease before and after the COVID-19 pandemic in a large pediatric heart disease center. Front Pediatr 2022;10:895408. https://doi.org/10.3389/fped.2022.895408
7. Đặng Thị Hải Vân, Phạm Thảo Nguyên. Đặc điểm tổn thương động mạch vành ở bệnh nhân Kawasaki không đáp ứng với truyền tĩnh mạch immunoglobulin. Tạp chí Nghiên cứu Y học 2021;143(7):123-133. https://doi.org/10.52852/tcncyh.v143i7.239
8. Ngô Anh Vinh, Nguyễn Văn Nam. Đặc điểm lâm sàng, cận lâm sàng bệnh Kawasaki và một số yếu tố liên quan đến tổn thương động mạch vành ở Bệnh viện Sản Nhi Nghệ An. Tạp chí Y học Việt Nam 2024;536(2). https://doi.org/10.51298/vmj.v536i2.8880
9. Hồ Sỹ Hà, Chu Văn Tường, Lê Nam Trà. Bệnh Kawasaki gặp tại Bệnh viện Nhi Trung ương. Tạp chí Y học Thực hành 2000;8:31-33.
10. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol 2020;16(7):391-405.